Pharnext, a Truffle Capital creation, fights Covid-19
How to find existing effective drugs, against coronavirus
Bloomberg : Diaccurate Scientists show how HIV disables Immune System
Truffle Capital Raises €250M Fund to Launch Life Science Startups
The French VC firm Truffle Capital has closed a fund worth €250M with a mission to nurture companies specializing in medical devices
Consortium with Nestlé Waters, PepsiCo and Suntory Beverage & Food
Impressive 12-month Efficacy and Safety Data from ABX464
FDA approval to launch a clinical feasibility study in the United States
Inclusion du premier patient dans l’essai clinique de Phase 2b (ABX464-103) d’Abivax visant le traitement de la rectocolite hémorragique
Le critère d'évaluation principal est la réduction du score de Mayo à 8 semaines. Les critères d'évaluation secondaires incluront la rémission clinique, l'amélioration constatée par endoscopie ainsi que la mesure du biomarqueur…
Inclusion of the first patient in Abivax's Phase 2b (ABX464-103) clinical trial for the treatment of hemorrhagic rectocolitis
The main evaluation criterion is the reduction of Mayo's score to 8 weeks.
Abivax treats first rheumatoid arthritis patient in Phase 2a clinical trial
The clinical trial was approved in the following four European countries: France, Poland, Czech Republic and Hungary. ABX464 is a drug candidate in oral adent tablet form with an innovative mechanism of action and has already demonstrated positive results in hemorrhagic rectocolitis, another chronic inflammatory disease with a biological profile closely similar to rheumatoid arthritis.
Entrée de Sofinnova au capital pour 12 M€
1st PET bottles from 100% biorecycled plastic waste
FDA grants Fast Track designation for the development of PTX3003 in the treatment of patients with Charcot-Marie-Tooth disease type 1a
Positive interim results from the first part of the PIVOT study
Positive interim results from the first part of the PIVOT study (10 patients), 70% of patients in this first cohort achieved a six-month survival with the bioprosthesis or a successful total transplant, healthy heart within 6 months of implantation of the device.